Guidance on Targeted ADCs for Lung Cancer

CME

Transforming Precision Lung Cancer Care: Expert Guidance on HER2-, HER3-, TROP2-, and B7-H3–Targeted ADCs

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

European Learners: 1.00 EBAC® CE Credit

Released: October 22, 2024

Expiration: May 31, 2025

David Planchard
David Planchard, MD, PhD
Egbert F. Smit
Egbert F. Smit, MD, PhD
Helena Yu
Helena Yu, MD

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Which of the following genomic alterations is actionable with an approved antibody–drug conjugate and should be tested for in all patients with metastatic NSCLC?

2.

Which of the following agents has been assessed in patients with advanced NSCLC and HER2 overexpression?

3.

A 58-yr-old woman was diagnosed with metastatic EGFR exon 19 deletion positive lung adenocarcinoma. She was initially treated with first-line osimertinib for 20 months, followed by 9 months on carboplatin/pemetrexed followed by pemetrexed maintenance. She now has disease progression with new liver lesions and new R pleural effusion. Repeat liquid biopsy demonstrates the EGFR exon 19 deletion and no new mutations.

Assuming approval of all these agents, what would be the best next treatment for the patient?

4.

For a patient with metastatic NSCLC receiving sacituzumab govitecan who develops grade 2 diarrhea that occurs during or shortly after infusion, which of the following strategies would you recommend to the mitigate risk of diarrhea at the next infusion?